Article Data

  • Views 615
  • Dowloads 138

Original Research

Open Access

The role of proteasome inhibitor MG132 in cisplatin resistant ovarian cancer

  • Bailing ZHANG1,2,3
  • Na GUO1,2,*,

1The Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, 610041 Chengdu, Sichuan, China

2Key laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, 610041 Sichuan, Chengdu, China

3The Department of Laboratory Medicine, The Second Affiliated Hospital of Nanchang University, 330006 Nanchang, Jiangxi, China

DOI: 10.22514/ejgo.2023.055 Vol.44,Issue 4,August 2023 pp.28-36

Submitted: 21 June 2022 Accepted: 16 November 2022

Published: 15 August 2023

*Corresponding Author(s): Na GUO E-mail: guona507@aliyun.com

Abstract

Platinum based combined chemotherapy have been proved to be the most effective drugs for the ovarian cancer treatment, but it is difficult to treat cisplatin resistant ovarian cancer. Carbobenzoxy-L-leucy-L-Leucyl-L-Leucinal (MG132) is a reversible tripeptide aldehyde proteasome inhibitor, the purpose of this study was to observe the effect of MG132 on cisplatin resistant ovarian cancer SKOV3 cell and OVCAR-3 cell the expression of autophagy and apoptosis related factors. The cells were divided into four groups: control, MG132, cisplatin, MG132 and cisplatin combination groups. Cell growth was detected by cell counting kit-8 (CCK-8) assay. The apoptotic rates of cells and the cell cycle were detected by a flow cytometer (FCM). The Beclin1, Light chain 3 (LC3) and Caspase3 was detected by western blotting and reverse transcription-polymerase chain reaction (RT-PCR). Detection of apoptotic bodies by 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI) staining. CCK-8 assay demonstrated that cell survival rate in the combination groups was lower than monotherapy group. FCM showed that apoptotic rates in the combination groups was higher than monotherapy group (p < 0.05). Western blotting and RT-PCR detected that Beclin1, LC3 and Caspase3 in the combination group were higher than monotherapy group (p < 0.05). DAPI staining showed the production of apoptotic bodies in the combination group and MG132 group. In conclusion, MG132 can inhibit the growth of cisplatin resistant ovarian cancer SKOV3 and OVCAR-3 cells, its inhibitory effect is related to apoptosis and autophagy, and it is expected to be a synergistic antitumor effect with cisplatin.


Keywords

MG132; Cisplatin; Resistant ovarian cancer; Apoptosis; Autophagy


Cite and Share

Bailing ZHANG,Na GUO. The role of proteasome inhibitor MG132 in cisplatin resistant ovarian cancer. European Journal of Gynaecological Oncology. 2023. 44(4);28-36.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017; 67: 7–30.

[2] Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, et al. Stage at diagnosis and ovarian cancer survival: evidence from the international cancer benchmarking partnership. Gynecologic Oncology. 2012; 127: 75–82.

[3] Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL. Metastatic gynecologic malignancies: advances in treatment and management. Clinical & Experimental Metastasis. 2018; 35: 521–533.

[4] Tossetta G, Fantone S, Montanari E, Marzioni D, Goteri G. Role of NRF2 in ovarian cancer. Antioxidants. 2022; 11: 663.

[5] Jarome TJ, Devulapalli RK. The ubiquitin-proteasome system and memory: moving beyond protein degradation. The Neuroscientist. 2018; 24: 639–651.

[6] Zwickl P, Voges D, Baumeister W. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. 1999; 354: 1501–1511.

[7] Konstantinova IM, Tsimokha AS, Mittenberg AG. Role of proteasomes in cellular regulation. International Review of Cell and Molecular Biology. 2008; 36: 59–124.

[8] Klionsky DJ. The molecular machinery of autophagy: unanswered questions. Journal of Cell Science. 2005; 118: 7–18.

[9] Lu K, den Brave F, Jentsch S. Pathway choice between proteasomal and autophagic degradation. Autophagy. 2017; 13: 1799–1800.

[10] Herman-Antosiewicz A, Johnson DE and Singh SV. Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells. Cancer Research. 2006; 66: 5828–5835.

[11] Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by Beclin 1. Nature. 1999; 402: 672–676.

[12] Liang XH, Kleeman LK, Jiang HH, Gordon G, Goldman JE, Berry G, et al. Protection against fatal sindbis virus encephalitis by Beclin, a novel Bcl-2-interacting protein. Journal of Virology. 1998; 72: 8586–8596.

[13] Kabeya Y. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. The EMBO Journal. 2000; 19: 5720–5728.

[14] Wu J, Dang Y, Su W, Liu C, Ma H, Shan Y, et al. Molecular cloning and characterization of rat LC3a and LC3B—two novel markers of au-tophagosome. Biochemical and Biophysical Research Communications. 2006; 339: 437–442.

[15] Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, et al. Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012; 120: 4513–4516.

[16] Liebermann DA, Hoffman B, Vesely D. P53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell Cycle. 2007; 6: 166–170.

[17] Goldberg AL. Development of proteasome inhibitors as research tools and cancer drugs. Journal of Cell Biology. 2012; 199: 583–588.

[18] Laussmann MA, Passante E, Düssmann H, Rauen JA, Würstle ML, Delgado ME, et al. Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8. Cell Death & Differentiation. 2011; 18: 1584–1597.

[19] Campagna R, Bacchetti T, Salvolini E, Pozzi V, Molinelli E, Brisigotti V, et al. Paraoxonase-2 silencing enhances sensitivity of A375 melanoma cells to treatment with cisplatin. Antioxidants. 2020; 9: 1238.

[20] Guo N, Peng Z, Zhang J. Proteasome inhibitor MG132 enhances sensitivity to cisplatin on ovarian carcinoma cells in vitro and in vivo. International Journal of Gynecologic Cancer. 2016; 26: 839–844.

[21] Wang J, Zhou J, Wu GS. Bim protein degradation contributes to cisplatin resistance. Journal of Biological Chemistry. 2011; 286: 22384–22392.

[22] Tenev T, Marani M, McNeish I, Lemoine NR. Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. Cell Death and Differentiation. 2001; 8: 256–320.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top